% | $
Quotes you view appear here for quick access.

BioLineRx, Ltd. Message Board

  • siamesekitty711 siamesekitty711 Feb 12, 2013 2:16 PM Flag

    Presentation is

    going well. 1020 explained very well. 1040 - talking about how the drug works like a cast for the heart (regulated as a device). Pilot study went well with no adverse events. Partner - Ikaria is based in NJ. Now discussing the rest of the pipeline.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • tkash0129 Feb 12, 2013 3:01 PM Flag

      So can I just digress and estimate this company value if BL-1020 is approved and takes SOME market share.

      If schizophrenia drug market is 6 Billion, and lets say BLRX gets 10% of the market share.

      600 million at that point

      Let's estimate the royalty from the BL-1020 is at 10%

      60 million dollars / year

      Market cap 60 mil at 4 / share.... that's 15 million shares outstanding??

      Include the approx. 3 million share dilution from the ADS to Orbimed

      18 million shares

      If the P/E ratio is even at 10, the capitalization of the company will be at 600 million

      600 million / 18 million shares = 33 dollars / share?? Is this correct??????

      Sentiment: Buy

      • 1 Reply to tkash0129
      • That would be a reasonable assumption. He also said BL-1040 might eventually be in a billion dollar space. There are now 21 million shares out in terms of ADS equivalents, that was in the presentation, but of course cash position is increased. Everybody interested can listen to the presentation again. He also said they looked at dozens of projects and only pursued only those that might prove fruitful. The other pipe line projects sounded interesting and are moving forward.

        Sentiment: Strong Buy

1.47+0.14(+10.53%)3:59 PMEST